5B4B7A3B-FD69-43EA-9C9C-FBE2845046CB
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.764783180026281
- age_years
- 65
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.636
- DNA_REPAIR+0.584
- MYC_TARGETS_V1+0.572
- MYC_TARGETS_V2+0.565
- G2M_CHECKPOINT+0.526
- INTERFERON_ALPHA_RESPONSE+0.434
- MTORC1_SIGNALING+0.427
- ANGIOGENESIS+0.407
- UNFOLDED_PROTEIN_RESPONSE+0.399
- GLYCOLYSIS+0.391
Top 10 suppressed
- KRAS_SIGNALING_DN-0.404
- HEDGEHOG_SIGNALING-0.265
- ESTROGEN_RESPONSE_EARLY-0.258
- UV_RESPONSE_DN-0.220
- APICAL_SURFACE-0.208
- MYOGENESIS-0.207
- SPERMATOGENESIS-0.185
- PANCREAS_BETA_CELLS-0.132
- BILE_ACID_METABOLISM-0.129
- ESTROGEN_RESPONSE_LATE-0.093
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4EA4A8AE-581A-4170-8062-99645CB41337 | — | — | 0.957 |
| 2 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.951 |
| 3 | 2E401C42-010F-4AFC-A362-B69426418626 | — | — | 0.950 |
| 4 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.948 |
| 5 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.942 |
| 6 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.941 |
| 7 | 9BB12A25-E833-4055-8CEF-814EA5454F11 | — | — | 0.940 |
| 8 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.936 |
| 9 | 1A0F3795-92C5-4887-8CD0-B19C763CF6EF | — | — | 0.935 |
| 10 | 05C1C0CC-8EAE-4924-B041-D448D280C192 | — | — | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.636 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.584 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.572 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.565 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.526 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.434 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.427 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.407 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.399 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.391 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.378 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.343 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.312 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.295 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.276 | Inavolisib | — uncovered |
| APOPTOSIS | 0.271 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.263 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.207 | Inavolisib | — uncovered |
| HYPOXIA | 0.201 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.201 | Inavolisib | — uncovered |